N
Nido Biosciences
Pperates in healthcare services
About Nido Biosciences
Nido Bio is a pioneering startup operating in the healthcare sector, specifically focusing on the development of transformative medicines for neurological diseases. The company is committed to addressing the rising prevalence of these complex diseases, which are increasingly posing significant challenges to healthcare professionals globally. Nido Bio's mission is to improve the quality of life for patients suffering from debilitating neurological conditions by providing effective treatment options.
Read full description
The company's primary market is patients suffering from rare and progressive neurological disorders such as Spinal and Bulbar Muscular Atrophy (SBMA), Amyotrophic Lateral Sclerosis (ALS), Rare Tauopathies, and Frontotemporal Dementia (FTD). These diseases, which often result in a progressive loss of function and significant impact on patients' daily lives, currently have no effective treatments available.
Nido Bio's business model revolves around the research, development, and commercialization of innovative medicines. The company generates revenue by developing and selling these novel treatments to healthcare providers who then administer them to patients. The company's multiple programs are designed to provide real solutions that can significantly improve the daily lives of patients suffering from these debilitating diseases.
In summary, Nido Bio is a healthcare startup dedicated to developing transformative medicines for rare and progressive neurological diseases. The company is committed to improving the lives of patients by providing effective treatment options that can help manage these debilitating conditions.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Cambridge, United States
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 59.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Nido Biosciences.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2023 | $87M | $346M | Bioluminescence Ventures | ↗ |
| SERIES AOther financing | Sep 2020 | $18M | $74M | Osage University Partners · Abingworth · 5AM Ventures · Eli Lilly | — |
Growth signals
Latest recorded traffic for Nido Biosciences is 260 monthly website visits, down 78.3% over the last three months. Nido Biosciences's team declined 40% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
5AM Ventures
Series A5 investors entered at this stage
Abingworth
Bessemer Venture Partners
Osage University Partners
Eli Lilly
Bioluminescence Ventures
Other known investors1 additional known investor
The University of British Columbia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nido Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nido Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.